Meeting Banner
Abstract #2750

Preclinical platform for the identification of deuterium magnetic resonance spectroscopy-based biomarkers of tumor metabolism

Georgios Batsios1, Meryssa Tran1, Celine Taglang1, Anne Marie Gillespie1, Sabrina Ronen1, Joseph Costello2, and Pavithra Viswanath1
1Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, 2Neurological Surgery, University of California San Francisco, San Francisco, CA, United States


Metabolic reprogramming is a fundamental hallmark of cancer, which can be exploited for non-invasive tumor imaging. Deuterium magnetic resonance spectroscopy (2H-MRS) recently emerged as a novel, clinically applicable method of non-invasively monitoring flux from 2H-labeled substrates to metabolic products. However, to date, preclinical studies have been performed in vivo, an endeavor that suffers from low-throughput and potential waste of animal lives, especially in treatment response studies. Here, we demonstrate the ability to quantify metabolism of 2H-MRS probes in live cell suspensions. Our studies will expedite the identification of novel 2H-MRS probes for imaging brain tumors and potentially other cancers.

This abstract and the presentation materials are available to members only; a login is required.

Join Here